| Literature DB >> 31694171 |
Kevin M Coombs1,2,3, Philippe F Simon1,4, Nigel J McLeish1, Ali Zahedi-Amiri1,2, Darwyn Kobasa1,4.
Abstract
Influenza A viruses (IAVs) are important animal and human emerging and re-emerging pathogens that are responsible for yearly seasonal epidemics and sporadic pandemics. IAVs cause a wide range of clinical illnesses, from relatively mild infections by seasonal strains, to acute respiratory distress during infections with highly pathogenic avian IAVs (HPAI). For this study, we infected A549 human lung cells with lab prototype A/PR/8/34 (H1N1) (PR8), a seasonal H1N1 (RV733), the 2009 pandemic H1N1 (pdm09), or with two avian strains, an H5N1 HPAI strain or an H7N9 strain that has low pathogenicity in birds but high pathogenicity in humans. We used a newly-developed aptamer-based multiplexed technique (SOMAscan®) to examine >1300 human lung cell proteins affected by the different IAV strains, and identified more than 500 significantly dysregulated cellular proteins. Our analyses indicated that the avian strains induced more profound changes in the A549 global proteome compared to all tested low-pathogenicity H1N1 strains. The PR8 strain induced a general activation, primarily by upregulating many immune molecules, the seasonal RV733 and pdm09 strains had minimal effect upon assayed molecules, and the avian strains induced significant downregulation, primarily in antimicrobial response, cardiovascular and post-translational modification systems.Entities:
Keywords: RNA virus infection; SOMAScan®; aptamers; emerging viruses; proteomics
Mesh:
Substances:
Year: 2019 PMID: 31694171 PMCID: PMC6893437 DOI: 10.3390/v11111028
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Numbers of significantly dysregulated A549 proteins induced by each Influenza A virus (IAV) strain.
| Number That Are Significant | Total Unique | PR8 | RV733 | pdm09 | H5N1 | H7N9 |
|---|---|---|---|---|---|---|
| and fold-change > 1.000 | 510 | 33 | 20 | 67 | 194 | 133 |
| and fold-change < 0.9999 | 15 | 7 | 38 | 166 | 168 | |
| and fold-change > 1.250 | 128 | 17 | 1 | 7 | 15 | 10 |
| and fold-change < 0.8000 | 1 | 1 | 14 | 57 | 65 | |
| and fold-change > 1.333 | 98 | 15 | 1 | 6 | 8 | 6 |
| and fold-change < 0.7500 | 1 | 1 | 6 | 45 | 56 | |
| and fold-change > 1.500 | 76 | 14 | 1 | 1 | 6 | 2 |
| and fold-change < 0.6667 | 1 | 1 | 4 | 32 | 45 | |
| and fold-change > 2.000 | 33 | 8 | 0 | 0 | 2 | 1 |
| and fold-change < 0.5000 | 0 | 0 | 2 | 11 | 19 | |
| and fold-change > 3.000 | 11 | 4 | 0 | 0 | 1 | 0 |
| and fold-change < 0.3333 | 0 | 0 | 0 | 4 | 7 | |
| and fold-change > 5.000 | 6 | 2 | 0 | 0 | 0 | 0 |
| and fold-change < 0.2000 | 0 | 0 | 0 | 2 | 4 |
Significance determined by T-test and Z-score as described in Materials & Methods. The 76 specific proteins significantly dysregulated >1.5-fold are listed in Table 2.
A549 proteins dysregulated by infection by indicated influenza strains.
| EntrezGene Symbol | Protein | Fold-Change Compared to Sham-Infected | ||||
|---|---|---|---|---|---|---|
| H1N1 Viruses | ||||||
| PR8 | RV733 | pdm09 | H5N1 | H7N9 | ||
|
| ||||||
| ISG15 | Ubiquitin-like protein ISG15 |
| 1.03 | 0.96 | 1.33 | 1.10 |
| OAS1 | 2′-5′-oligoadenylate synthase 1 |
| 0.99 | 1.08 | 0.97 | 0.96 |
| CCL5 | C-C motif chemokine 5 |
| 1.06 | 1.09 |
|
|
| STAT1 | Signal transducer and activator of transcription 1-alpha/beta |
| 1.26 | 0.85 | 1.02 | 1.00 |
| B2M | Beta-2-microglobulin |
| 0.97 | 1.11 | 1.12 | 0.99 |
| APOL1 | Apolipoprotein L1 |
| 0.98 | 0.99 | 0.99 | 0.92 |
| CD274 | Programmed cell death 1 ligand 1 |
| 1.06 | 1.05 | 1.27 | 1.13 |
| CTSS | Cathepsin S |
| 0.99 | 1.05 | 0.79 |
|
| SERPINE1 | Plasminogen activator inhibitor 1 |
| 1.00 | 1.10 | 0.89 | 0.70 |
| IFNL1 | Interferon lambda-1 |
| 1.00 | 0.99 |
| 1.21 |
| F2 | Thrombin |
| 1.03 | 1.00 | 0.97 | 0.89 |
| PLAUR | Urokinase plasminogen activator surface receptor |
| 0.98 | 1.05 | 1.05 | 0.85 |
| MDK | Midkine |
| 1.01 | 0.97 | 1.02 | 0.93 |
| CFB | Complement factor B |
| 1.04 | 1.03 | 1.03 | 0.96 |
| THPO | Thrombopoietin | 1.01 |
| 1.01 | 1.00 | 1.10 |
| L1CAM | Neural cell adhesion molecule L1 | 1.21 | 1.28 |
|
| 1.47 |
| CXCL8 | Interleukin-8 | 1.26 | 1.00 | 0.99 |
|
|
| CD207 | C-type lectin domain family 4 member K | 1.10 | 1.05 | 1.06 |
| 1.38 |
| F9 | Coagulation factor IX | 2.21 | 1.03 | 1.14 |
| 1.29 |
|
| ||||||
| PPID | Peptidyl-prolyl cis-trans isomerase D |
| 1.15 | 0.95 | 0.97 | 1.03 |
| TGM3 | Protein-glutamine gamma-glutamyltransferase E | 0.88 |
| 1.21 | 0.75 | 0.90 |
| PGAM1 | Phosphoglycerate mutase 1 | 1.05 | 0.83 |
|
|
|
| MDH1 | Malate dehydrogenase, cytoplasmic | 1.01 | 1.02 |
| 0.59 | 0.83 |
| LDHB | L-lactate dehydrogenase B chain | 0.97 | 1.19 |
| 0.84 | 1.02 |
| ENO1 | Alpha-enolase | 0.91 | 0.96 |
| 0.77 | 0.82 |
| PCSK9 | Proprotein convertase subtilisin/kexin type 9 | 0.80 | 0.92 | 1.07 |
|
|
| DKK1 | Dickkopf-related protein 1 | 0.85 | 0.87 | 0.92 |
|
|
| DKK4 | Dickkopf-related protein 4 | 0.88 | 0.91 | 0.97 |
|
|
| APP | Amyloid beta A4 protein | 0.93 | 0.94 | 0.99 |
|
|
| SPINT2 | Kunitz-type protease inhibitor 2 | 0.93 | 0.87 | 0.95 |
|
|
| TNFRSF4 | Tumor necrosis factor receptor superfamily member 4 | 1.01 | 0.53 | 0.56 |
| 0.54 |
| IGFBP4 | Insulin-like growth factor-binding protein 4 | 1.28 | 0.95 | 1.06 |
|
|
| PGD | 6-phosphogluconate dehydrogenase, decarboxylating | 0.98 | 1.12 | 0.80 |
| 0.66 |
| FN1 | Fibronectin | 1.12 | 0.94 | 0.95 |
|
|
| TGFBI | Transforming growth factor-beta-induced protein ig-h3 | 0.87 | 0.95 | 0.95 |
|
|
| SGTA | Small glutamine-rich tetratricopeptide repeat-containing protein alpha | 0.93 | 1.01 | 0.65 |
| 0.80 |
| GAPDH | Glyceraldehyde-3-phosphate dehydrogenase | 0.97 | 1.00 | 0.70 |
| 0.83 |
| FSTL3 | Follistatin-related protein 3 | 1.49 | 0.92 | 1.04 |
|
|
| FN1 | Fibronectin Fragment 3 | 1.12 | 0.95 | 0.94 |
|
|
| CTSA | Lysosomal protective protein | 0.75 | 0.94 | 1.04 |
|
|
| MICB | MHC class I polypeptide-related sequence B | 0.88 | 0.93 | 1.00 |
|
|
| NOTCH3 | Neurogenic locus notch homolog protein 3 | 1.06 | 0.90 | 0.95 |
|
|
| PKM2 | Pyruvate kinase PKM | 0.80 | 1.10 | 1.38 |
| 0.81 |
| LRIG3 | Leucine-rich repeats and immunoglobulin-like domains protein 3 | 1.50 | 0.87 | 0.92 |
|
|
| MFGE8 | Lactadherin | 0.91 | 0.94 | 1.05 |
|
|
| PEX5 | Peroxisomal targeting signal 1 receptor | 0.98 | 0.71 | 0.73 |
| 0.75 |
| WNK3 | Serine/threonine-protein kinase WNK3 | 1.10 | 0.93 | 0.86 |
| 0.77 |
| TNFRSF21 | Tumor necrosis factor receptor superfamily member 21 | 0.96 | 0.92 | 0.96 |
|
|
| SFRP1 | Secreted frizzled-related protein 1 | 1.27 | 1.00 | 0.98 |
|
|
| TNFRSF1A | Tumor necrosis factor receptor superfamily member 1A | 0.74 | 0.97 | 1.09 |
|
|
| FSTL1 | Follistatin-related protein 1 | 1.28 | 0.92 | 1.02 |
|
|
| IGFBP7 | Insulin-like growth factor-binding protein 7 | 1.06 | 0.96 | 1.00 |
|
|
| NRP1 | Neuropilin-1 | 1.09 | 0.94 | 0.89 |
|
|
| CSF3R | Granulocyte colony-stimulating factor receptor | 1.03 | 0.75 | 0.83 |
| 0.75 |
| C3 | C3a anaphylatoxin des Arginine | 1.12 | 0.96 | 1.00 |
|
|
| CFH | Complement factor H | 1.54 | 1.00 | 0.96 |
|
|
| STC1 | Stanniocalcin-1 | 1.19 | 0.89 | 1.05 | 0.69 |
|
| FGFR1 | Fibroblast growth factor receptor 1 | 1.02 | 0.94 | 1.02 | 0.69 |
|
| CTSV | Cathepsin L2 | 0.83 | 0.98 | 1.08 | 0.74 |
|
| CST3 | Cystatin-C | 1.39 | 0.94 | 1.10 | 0.86 |
|
| PLXNB2 | Plexin-B2 | 1.05 | 1.02 | 1.14 | 0.71 |
|
| LGALS8 | Galectin-8 | 1.18 | 0.92 | 0.92 | 0.78 |
|
| NRG1 | Neuregulin-1 | 1.21 | 1.03 | 1.24 | 0.94 |
|
| GNS | N-acetylglucosamine-6-sulfatase | 0.95 | 1.04 | 1.09 | 0.75 |
|
| MICA | MHC class I polypeptide-related sequence A | 0.85 | 1.04 | 1.18 | 0.68 |
|
| LAMA1 | Laminin | 0.76 | 1.09 | 1.14 | 0.79 |
|
| THBS1 | Thrombospondin-1 | 1.05 | 1.01 | 1.04 | 0.68 |
|
| TIMP2 | Metalloproteinase inhibitor 2 | 0.97 | 0.93 | 1.03 | 0.85 |
|
| MMP7 | Matrilysin | 0.93 | 0.99 | 1.03 | 0.93 |
|
| LCN2 | Neutrophil gelatinase-associated lipocalin | 0.78 | 0.96 | 1.03 | 0.87 |
|
| GRN | Granulins | 1.04 | 0.96 | 1.04 | 0.67 |
|
| TFPI | Tissue factor pathway inhibitor | 0.80 | 1.03 | 1.03 | 1.10 |
|
| GFRA1 | GDNF family receptor alpha-1 | 0.77 | 0.97 | 0.99 | 0.75 |
|
| MET | Hepatocyte growth factor receptor | 1.23 | 1.03 | 1.11 | 0.89 |
|
| KIR2DL4 | Killer cell immunoglobulin-like receptor 2DL4 | 0.92 | 1.01 | 0.92 | 0.77 |
|
| LGALS3BP | Galectin-3-binding protein | 1.49 | 0.97 | 1.01 | 0.83 |
|
Values represent protein fold-changes compared to mock-infected. Fold-changes with significance <0.05 and with proteins significantly upregulated ≥1.50-fold are indicated in red, and proteins significantly downregulated ≤0.666-fold are indicated in green. Proteins sorted first by upregulation and from left-most virus column to right-most; then sorted by downregulation from left to right.
Figure 1Protein dysregulation characteristics of IAV-infected A549 cells. (A) Volcano plots of dysregulated proteins. The dashed horizontal line corresponds to p-value 0.05. Proteins significantly upregulated ≥1.5-fold (≥+0.585 Log2) are indicated with larger red circles and proteins downregulated ≥1.5-fold (≤−0.585 Log2) are indicated with larger green circles. (B) Pairwise R2 comparisons of indicated virus-infected cellular proteins, with (C) Individual proteins of selected pairs graphically presented.
Figure 2Global dysregulation of A549 proteome by various IAV. All significantly dysregulated A549 proteins altered by >1.33-fold were uploaded to the Ingenuity Pathway Analysis (IPA) tool and each virus’ “Disease Functions” mapped. Orange color represents upregulated proteins within specific disease clusters, blue represents downregulated proteins, grey and purple represent proteins not significantly regulated, and white were not measured by the SOMAmers.
Figure 3Significant differentially regulated A549 protein networks. (A–D) correspond to indicated IPA-defined Networks. Proteins and their levels of regulation were imported into the IPA® tool and interacting pathways were constructed under default settings. Four of the top dysregulated A549 cell networks that contain 12 or more “focus” molecules (molecules significantly up- or downregulated) and that have network scores ≥20 are depicted. Red: Significantly upregulated proteins; Pink: moderately upregulated proteins; Gray: proteins within the SOMAscan panel, but whose expression was not significantly up- or downregulated by indicated infection; Light Green: moderately downregulated proteins; Dark Green: significantly downregulated proteins; White: proteins known to be in network, but not covered within SOMAscan panel. Dashed lines represent predicted or indirect interactions; solid lines represent direct known interactions.
Figure 4IPA-predicted most affected bio-functions by differentially-expressed proteins by each IAV strain. The default IPA Z-score settings for activation (+1.96σ) and inhibition (−1.96σ) were used. Z-scores are indicated on upper X-axes of each graph and by horizontal bars, and −Log10 p-values (bottom X-axes) are depicted by ●. There were no significantly dysregulated bio-functions by RV733 or pdm09.
Figure 5Comparison of cellular canonical signaling pathways affected by various IAV strains. Only the top 20 IPA®-identified canonical pathways and their indicated p-values are shown. RV733 and pdm09 did not activate any of these pathways.